Skip to main content

You must have JavaScript enabled in order to access this part of the site. Please enable JavaScript and then reload this page in order to continue.

Changes to Hepatitis C Prior Authorization Criteria Begin September 1, 2021

Last updated on

Beginning September 1, 2021, Medicaid will expand coverage of the hepatitis C virus clinical prior authorization criteria to include all metavir fibrosis scores. The Texas Health and Human Services Commission (HHSC) will modify the requirements as follows:

  • Treatment with a direct-acting antiviral (DAA) medication on the formulary will be available to Medicaid clients regardless of metavir fibrosis scores.
  • HHSC no longer restricts the prescribing of a DAA medication to a specialist provider. These medications can now be prescribed by general practitioners as well.
  • A drug screening will no longer be required.
  • No additional refill authorization is required to continue DAA treatment.

HHSC requires the clinical prior authorization criteria for all Medicaid clients, both fee-for-service and managed care. Providers should continue using the current criteria and forms until August 31, 2021. The following revised hepatitis C prior authorization forms for Medicaid fee-for-service processing will be available on September 1, 2021:

  • Antiviral Agents for Hepatitis C Virus – Initial Request (HHS Form 1335)
  • Antiviral Agents for Hepatitis C Virus – Initial Request – Addendum (HHS Form 1342)

HHSC will no longer require the Antiviral Agents for Hepatitis C Virus – Refill Request (HHS Form 1336) on September 1, 2021.

Each Medicaid managed care organization (MCO) will have its own version of the hepatitis C prior authorization forms with their specific contact information. Contact each MCO for prior authorization forms and submission instructions using the Prescriber Assistance Chart.

Contact vdp-formulary@hhsc.state.tx.us with comments or any questions.